Analysts Lift Biopharma, Trim Industrials

Analyst consensus shifted upward for biopharma names and lower for materials and chemicals on August 1.

Regeneron Pharmaceuticals saw its average analyst target price nudge up to $832.43. The $73.8 billion biotech carries just 3.5% short interest. 17 analysts maintain buy ratings. The positive revision follows ongoing strength in the company's drug portfolio.

Biogen also received a target lift, with consensus edging to $234.35. 23 analysts hold buy ratings on the stock. The biopharma sector saw broad upward revisions today.

West Pharmaceutical Services gained fresh analyst momentum. Target prices moved to $404.73. 14 of 17 covering analysts rate it a buy.

On the downside, Martin Marietta Materials saw its consensus target trimmed to $671.61. The aggregates giant has a $32.4 billion market cap. Only 13 buy ratings remain versus 8 holds.

Linde also saw a modest target cut to $545.54. The industrial gas leader still commands 20 buy ratings from analysts.

Eaton Corporation received a fresh new recommendation with a consensus target of $452.95 from 16 analysts. No prior consensus existed for comparison.